{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:00:16Z","timestamp":1792144816761,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":569,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cmi.2022.02.042","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T02:35:11Z","timestamp":1646879711000},"page":"1321-1327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies"],"prefix":"10.1016","volume":"28","author":[{"given":"Khalis","family":"Mustafayev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrys","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.02.042_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2022.02.042_bib2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.02.042_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community Oncology practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cmi.2022.02.042_bib4","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2022.02.042_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2022.02.042_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","article-title":"Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis","volume":"164","author":"Paul","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2022.02.042_bib7","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/cncr.30729","article-title":"Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy","volume":"123","author":"Hwang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2022.02.042_bib8","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2022.02.042_bib9","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2022.02.042_bib10","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2022.02.042_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2022.02.042_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12072-019-09966-z","article-title":"Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers","volume":"13","author":"Nishida","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cmi.2022.02.042_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.cmi.2022.02.042_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cmi.2022.02.042_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2020.08.041","article-title":"Hepatitis B reactivation and immune check point inhibitors","volume":"53","author":"Godbert","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cmi.2022.02.042_bib16","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1093\/annonc\/mdx502","article-title":"HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma","volume":"28","author":"Koksal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2022.02.042_bib17","first-page":"5985131","article-title":"A\u00a0rare case of pembrolizumab-induced reactivation of hepatitis B","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.cmi.2022.02.042_bib18","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","article-title":"Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy","volume":"31","author":"Lake","year":"2017","journal-title":"Aids"},{"key":"10.1016\/j.cmi.2022.02.042_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/00000434-201710001-02146","article-title":"Hepatitis B reactivation after administration of pembrolizumab (KEYTRUDA): a unique case report: 2145","volume":"112","author":"Ragunathan","year":"2017","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"10.1016\/j.cmi.2022.02.042_bib20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.14309\/ajg.0000000000001142","article-title":"Hepatitis flare during immunotherapy in patients with current or past hepatitis B virus infection","volume":"116","author":"Wong","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2022.02.042_bib21","doi-asserted-by":"crossref","first-page":"e001072","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cmi.2022.02.042_bib22","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2021.06.019","article-title":"Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment","volume":"20","author":"Yoo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2022.02.042_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cmi.2022.02.042_bib24","doi-asserted-by":"crossref","first-page":"19013","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.cmi.2022.02.042_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clml.2019.12.006","article-title":"Hepatitis B virus-associated liver failure in a patient with B-cell non-hodgkin lymphoma after anti-cancer therapy including ibrutinib","volume":"20","author":"Malek","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cmi.2022.02.042_bib26","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","article-title":"Risk of hepatitis B virus reactivation in patients treated with ibrutinib","volume":"131","author":"Hammond","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.02.042_bib27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/hepr.13575","article-title":"Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course","volume":"51","author":"Tsuruya","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cmi.2022.02.042_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.02.042_bib29","doi-asserted-by":"crossref","first-page":"685706","DOI":"10.3389\/fonc.2021.685706","article-title":"HBV reactivation during the treatment of non-hodgkin lymphoma and management strategies","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cmi.2022.02.042_bib30","first-page":"160","article-title":"Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis","volume":"21","author":"Cheung","year":"2020","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.cmi.2022.02.042_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","article-title":"Isatuximab for the treatment of relapsed\/refractory multiple myeloma","volume":"20","author":"Richardson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cmi.2022.02.042_bib32","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.02.042_bib33","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/cells8121522","article-title":"Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.cmi.2022.02.042_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2022.02.042_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3960\/jslrt.19034","article-title":"Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy","volume":"60","author":"Kikuchi","year":"2020","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.cmi.2022.02.042_bib36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2022.02.042_bib37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2022.02.042_bib38","doi-asserted-by":"crossref","first-page":"e1372-5","DOI":"10.1093\/cid\/ciab302","article-title":"Reactivation of resolved hepatitis B after daratumumab for multiple myeloma","volume":"73","author":"Lee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.02.042_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.02.042_bib40","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2022.02.042_bib41","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5694\/mja2.50160","article-title":"Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement","volume":"210","author":"Doyle","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.cmi.2022.02.042_bib42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12185-015-1750-z","article-title":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy","volume":"101","author":"Totani","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cmi.2022.02.042_bib43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hepr.12117","article-title":"Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"44","author":"Nakano","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cmi.2022.02.042_bib44","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/hepr.12513","article-title":"Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"45","author":"Ifuku","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cmi.2022.02.042_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.02.042_bib46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s40425-019-0790-y","article-title":"Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma","volume":"7","author":"Wei","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cmi.2022.02.042_bib47","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.02.042_bib48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.16951","article-title":"Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy","volume":"191","author":"Liu","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2022.02.042_bib49","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2020004907","article-title":"Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy","volume":"136","author":"Cao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2022.02.042_bib50","doi-asserted-by":"crossref","first-page":"e000927","DOI":"10.1136\/jitc-2020-000927","article-title":"Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus","volume":"8","author":"Han","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cmi.2022.02.042_bib51","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2022.02.042_bib52","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2022.02.042_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2022.02.042_bib54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/imt-2020-0273","article-title":"Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?","volume":"13","author":"De Keukeleire","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cmi.2022.02.042_bib55","article-title":"1148PDImmunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C","volume":"28:Suppl. 5","author":"Rai","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2022.02.042_bib56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A\u00a0clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2022.02.042_bib57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cmi.2022.02.042_bib58","series-title":"Safety of immune checkpoint inhibitors in cancer patients with chronic hepatitis C infection: a prospective observational study","author":"Yibirin","year":"2020"},{"key":"10.1016\/j.cmi.2022.02.042_bib59","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiac.2021.07.018","article-title":"Successful treatment by glecaprevir\/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: case report and review of the literature","volume":"27","author":"Yamazaki","year":"2021","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2022.02.042_bib60","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22001197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22001197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:31:27Z","timestamp":1761118287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22001197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1198743X22001197"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.02.042","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}